Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

With this in mind, let's check out two no-brainer biotech stocks to buy right now. Moderna is an mRNA specialist, and this technology is delivering compelling results across a pipeline of late ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant ...

As a result of the stop work order, Vaxart said it had been forced to lay off 10% of its workforce. The company entered the ...

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...

Story Feb. 13 - Moderna: The big biotech is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees. The IT workforce reductions come as ...

The 10 most innovative biotech companies of 2025 are leveraging ... toxicity than RNA-based cancer vaccines (one of which, from Moderna, is in phase 3 trials). IO’s lead candidate, IO102-IO103 ...